Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR1 | Q04771 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | BRD4 | O60885 | 6/20 | 0.37 |
| ▸ | ALDH3A1 | P30838 | 2/20 | 0.37 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | PAK4 | O96013 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | BCR | P11274 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25513270 | 0.85 | ACVR1 (0.53) | ACVR1L3MBTL1BRD4ALDH3A1NOD1 | |
| SCHEMBL2186236 | 0.84 | ACVR1 (0.50) | ACVR1L3MBTL1BRD4ALDH3A1NOD1 | |
| SCHEMBL25201366 | 0.81 | ACVR1 (0.68) | ACVR1 | |
| SCHEMBL28978678 | 0.80 | PAK4 (0.43) | ACVR1HTTPAK4JAK2 | |
| SCHEMBL12363406 | 0.78 | JAK2 (0.60) | ACVR1JAK2ABL1 | |
| SCHEMBL2244532 | 0.77 | ACVR1 (0.38) | ACVR1ALDH3A1PAK4YTHDC1JAK2 | |
| SCHEMBL2241322 | 0.75 | L3MBTL1 (0.46) | L3MBTL1BRD4ALDH3A1NOD1POLB | |
| SCHEMBL31507532 | 0.71 | L3MBTL1 (0.40) | ACVR1L3MBTL1BRD4ALDH3A1NOD1 | |
| SCHEMBL22055000 | 0.71 | PIK3C3 (0.48) | L3MBTL1HTTPAK4ALDH1A1 | |
| SCHEMBL29392029 | 0.69 | NTRK1 (0.42) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201628-A1 | HETEROCYCLIC JAK KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2011-08-18 | — | — | US | disclosed |
| US-20110201628-A1 | HETEROCYCLIC JAK KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2011-08-18 | — | — | US | disclosed |
| WO-2010038060-A1 | HETEROCYCLIC JAK KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201628-A1 | HETEROCYCLIC JAK KINASE INHIBITORS | JAK2, JAK1, JAK3 | ACVR1 1794/4885L3MBTL1 4165/4885BRD4 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.